Drug Database
PR

prasterone (Mylis)

✓ Approved

Merck & Co. · AR · Small Molecule

What is prasterone?

prasterone is a small molecule developed by Merck & Co.. It is approved for therapeutic indications.

Drug Profile

Brand NamesMylis
CompanyMerck & Co.
Drug ClassSmall Molecule
Molecular TargetAR
StatusApproved

Mechanism of Action

Molecular Targets

prasterone acts on 1 molecular target:

ARandrogen receptor (DHTR, AR8)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

prasterone is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresLabour induction✓ Approved

Related Research Articles

PubMedHuman reproduction open2026-06-08

Likelihood of childbirth in women with one versus two ovaries: a Swedish population-based study of women treated with unilateral oophorectomy for benign indications.

Lind Tekla T, Nilsson Hanna P HP, Franko Mikael Andersson MA, Rodriguez-Wallberg Kenny A KA

What is the likelihood of future childbirth in women undergoing unilateral oophorectomy (UO) for benign indications, when compared to age-matched women with intact ovaries? A significantly reduced likelihood of future childbirth was observed in women with a history of UO, when compared to women with intact ovaries. At the time of this study, the prevailing view is that a single ovary is sufficient to maintain fertility. This is the first large-scale observational study reporting an association between UO for benign indications and a decreased chance of future childbirth in a population-based cohort that was followed until the end of reproductive age. This population-based register study included all Swedish women born 1955-1966, followed until the end of female reproductive age. We identified 17 856 women who underwent UO (exposed) and 171 731 age-matched controls. After exclusions, the exposed cohort consisted of 10 469 women of fertile age with a benign indication for UO and 101 753 age-matched controls. All cases of UO were identified by surgery codes and diagnosis of benign diseases, and up to 10 controls per case, matched by age and county, were used in the analysis. Childbirth data were collected from the Swedish Medical Birth Register, and childbirth rates were compared between exposed cases and age-matched controls. The childbirth rate post-surgery was lower in women with UO compared to age-matched controls having intact ovaries: 25.5% versus 28.7%, respectively (risk ratio (RR) 0.89; confidence interval (95% CI) 0.86-0.91). Subgroup analysis of women who were nulliparous at the time of UO (N = 4083) versus their age-matched controls (N = 18 770) also indicated a lower childbirth rate: 41.3% vs 66%, respectively (RR 0.63; 95% CI 0.61-0.65). Additionally, an interaction analysis among the nulliparous women indicated that the reduced likelihood of having children was associated with older age at the time of UO. In this register-based study, the desire for pregnancy could not be captured, and it was unknown if it was similar among cases and controls. Although malignant indications of UO could be excluded in the study, the histopathology of the removed ovaries was not available; thus, it was not possible to adjust for specific diseases potentially affecting fertility, and therefore, residual confounding is a limitation. Additional limitations included the lack of adjustment for lifestyle factors, as such data was only available from the medical birth register, and thus only accessible for the women who had given birth. This large population-based study demonstrates a significant association between unilateral oophorectomy for benign indications and a reduced likelihood of subsequent childbirth; however, causality cannot be inferred from these observational data. This work was funded by the Swedish Cancer Society (20 0170 F), the Swedish Research Council (Dnr 2021-06116 and Dnr 2023-01872), the Radiumhemmets Research Funds Grant for clinical researchers 2020-2026, the Childhood Cancer Fund (Dnr PR2022-0081), the Stockholm County Council (FoUI-953912) and the Karolinska Institutet Research grants Dnr 2020-01963 to K.A.R.W.The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The authors had full access to all study data and the final responsibility for the decision to submit for publication.K.A.R.W. has received: research grants from NovoNordisk, Merck, Gideon Richter and Ferring Pharmaceuticals; royalty for Student Literature (medical text book), Sweden; consulting fees from the Swedish Ministry of Health and Welfare as expert in assisted reproduction and fertility preservation for transgender people; consulting fees from SpringWorks; honoraria from Roche and Pfizer for chairmanship and lectures for education of oncologists; honoraria from Organon for lectures for ob/gyn and reproductive medicine specialists; and honoraria from IBSA for Advisory Board for educational events. K.AR.W. has also received support from Organon for participation in Journées Fertilité 2023, Paris, France, and support from Region Stockholm for participation as chair of the Swedish Interest Group in Reproductive Medicine Fert-ARG, for the Swedish Society of Obstetrics and Gynecology SFOG; participates at advisory board for Merck, Nordic countries, and on an advisory board for Ferring, National coordinator of study; and has received Time-lapse equipment for pre-clinical research from Merck pharmaceuticals and a grant for experimental in vitro research from Ferring Pharmaceuticals. The remaining authors have no conflicts of interest to declare. N/A.

PubMedWorld journal of surgical oncology2026-06-01

Trapezoidal tunnel intracorporeal esophagogastric anastomosis technique in laparoscopic-assisted proximal gastrectomy: technical notes and preliminary experience.

Sakurazawa Nobuyuki N, Kakinuma Daisuke D, Hagiwara Nobutoshi N, Kogo Hideki H et al.

Proximal gastrectomy (PG) is a curative surgical option that can also improve quality of life. Although esophagogastric anastomosis is a simple one-site procedure, reflux esophagitis remains a concern. This study presents an esophagogastric anastomosis technique that simplifies intra-abdominal manipulation by forming a trapezoidal tunnel in the residual stomach through extra-abdominal manipulation. We then evaluated the feasibility and functional outcomes of this technique. We retrospectively analyzed clinical data from 12 consecutive patients who underwent laparoscopic PG using the trapezoidal tunnel technique between November 2017 and September 2020 at Nippon Medical School Chiba Hokuso Hospital and between October 2020 and May 2022 at Nippon Medical School Hospital. Demographic and clinical pathological characteristics, preoperative details, and postoperative outcomes were analyzed. Reflux and stenosis status was assessed via endoscopy during follow-up conducted at least 1 year after surgery. Laparoscopic PG using the trapezoidal tunnel technique was successfully performed in all 12 cases. The mean operative time was 262 (195-362) minutes (including 57 [40-89] minutes for reconstruction). No postoperative complications of Clavien-Dindo grade II or higher were observed. The mean hospital stay was 12 (10-21) days. Endoscopic findings during postoperative follow-up (61 [14-89 months]) were normal, except for one patient who developed Los Angeles classification grade A esophagitis. Notably, no anastomotic strictures were identified. The trapezoidal tunnel technique is a feasible approach for anti-reflux reconstruction following laparoscopic PG that simplifies intra-abdominal surgical techniques while maintaining favorable postoperative clinical outcomes. Given the retrospective nature of the cases analyzed, further large-scale clinical trials are essential to verify the safety and efficacy of this technique.

PubMedWorld journal of urology2026-06-01

Navigating the challenges of overactive bladder management in women.

Braga Andrea A, Goldman Howard B HB, Padoa Anna A, Serati Maurizio M

Overactive bladder (OAB) is common among women, increases in prevalence with age, and exerts a considerable physical, psychological and socioeconomic burden. This narrative review discusses issues specific to the management of OAB in women. The review is based on discussions at a symposium held at the International Urogynecological Association/European Urogynaecological Association meeting (Barcelona, Spain; June 2025) supplemented by a PubMed search of articles (published in English since 1 January 2020) describing current treatment practices, unmet clinical needs and future directions for the management of OAB in women. The pathophysiology of OAB in women is multifactorial, involving detrusor overactivity, urothelial and sensory dysfunction, and central nervous system dysregulation, with additional contributions from hormonal and age-related changes. Management of OAB has evolved toward an individualised, stepwise approach. Behavioural and lifestyle interventions remain first-line therapy, followed by pharmacological options, such as antimuscarinics and β3-adrenergic agonists. For refractory cases, onabotulinumtoxin A and neuromodulation are established third-line treatments. Local oestrogen therapy or prasterone may provide benefit in selected postmenopausal women, whereas radiofrequency and urethral bulking strategies remain investigational. Emerging evidence supports newer β3-agonists, such as vibegron, which may provide comparable efficacy to established β3-agonists (e.g. mirabegron) with improved cardiovascular tolerability. Treatment selection for women with OAB should consider comorbidities, drug safety, cognitive and cardiovascular risk in older patients, and challenges with adherence. Further research into underlying mechanisms, long-term outcomes and strategies to optimise treatment adherence will be essential to improve symptom control and quality of life for women living with OAB.

PubMedHuman reproduction (Oxford, England)2026-05-29

Cleavage stage versus blastocyst stage transfers in patients with a single zygote: an emulated target trial.

Fitzgerald Oisin O, Li Wentao W, Vallence Catherine C, Chambers Georgina M GM et al.

Is the live birth rate higher for cleavage stage embryos compared to blastocysts in patients with a single zygote following oocyte fertilization using IVF or ICSI? Among patients with only a single zygote, transfer at cleavage stage was observed to result in a higher live birth rate than transfer at blastocyst stage. Existing evidence suggests that blastocyst transfer is superior to cleavage stage in terms of live birth rate per embryo transfer, cumulative live birth rate, and time to pregnancy with three or more zygotes. However, whether these findings generalize to cohorts with less than three zygotes remains unclear. This target trial emulation, with live birth as the primary outcome, involved a retrospective analysis of 11 163 nulliparous patients who undertook ART in Australia and New Zealand between 2009 and 2022. Participants were included in the study if they were undergoing their first-ever stimulated ART cycle resulting in a single zygote following fertilization using IVF or ICSI. In this cohort, there were 6505 patients who received a cleavage stage transfer, 2216 who received a blastocyst stage transfer, and 2442 who had no embryo available for transfer following embryo culture, with the intended day of transfer unknown for these patients. We modelled a comparison of intended transfer of a cleavage or blastocyst using g-computation within the target trial emulation framework. This involved fitting models that estimated the chance that embryo would survive to cleavage or blastocyst stage based on patient characteristics, and if it did so, the chance of a live birth when it is transferred. These models were used to simulate an idealized randomized controlled trial (target trial) on our retrospective cohort. We found that compared to blastocyst transfers, cleavage stage transfers were associated with a higher live birth rate per couple in this cohort (12.5% vs 10.1%), with an adjusted relative risk of 1.24 (95% CI: 1.15-1.50). This effect increased with female age from 35 years, with a relative risk of 1.34 (95% CI: 1.15-1.57) in a 35-year-old and 1.51 (95% CI: 1.25-1.80) in a 40-year-old woman. This is likely due to the high rate of embryo attrition between the cleavage and blastocyst stages; our models predict that on average 92.0% of zygotes would survive to cleavage stage, compared to 58.9% and 49.9% surviving to the blastocyst stage at ages 35 and 40 years. The originally intended/planned day of embryo transfer, i.e. cleavage stage or blastocyst, is not recorded in the data source, only the actual day of transfer. This required utilization of a multinomial mixture model that estimates the cleavage and blastocyst embryo development rates as a sub-model, using the year of treatment as an external source of variation (in additional to patient factors) for predicting the intended treatment group. As with any causal analysis using retrospectively collected observational data, the results are dependent on the accuracy of our modelling assumptions which cannot be verified. Additionally, the potential confounder of embryo quality on the day of transfer was not available. These results highlight the role target trial emulation can play in filling evidence gaps for patient cohorts excluded from existing RCTs, and where the prospect for future RCTs is limited due to sample size constraints or ethical considerations. Further, the assessment of new ART technologies and procedures needs to be stratified by markers of patient prognosis (in this case, female age and number of available zygotes), and there should be caution in generalizing the findings to a different group. This study was funded by the 2024 Ferring Australia Reproductive Medicine Research Grant Scheme. O.F., G.M.C., and L.R. are the listed investigators on this grant paid to UNSW Sydney. Ferring had no role in designing, analysing, interpreting, or reviewing the study. W.L. declares that they are a Human Reproduction Deputy Editor. L.R. declares consulting fees from Besins, Merck, and Organon, speaker's fees from Besins, travel support from Gedeon Richter, and shares in Monash IVF Group (ASX: MVF). C.V. declares receipt of gift vouchers as honorarium for consumer input to the study as part of their membership of UNSW YourIVFSuccess/National Perinatal Epidemiology and the Statistics Unit Consumer Advisory Group. The remaining authors have no conflicts of interest to declare. N/A.

PubMedCurrent zoology2026-05-28

Integrating habitat and population dynamics to uncover dispersal-driven persistence in a reintroduced Crested Ibis metapopulation.

Tuohetahong Yilamujiang Y, Tian Chunpo C, Lu Ruyue R, Ding Sheng S et al.

Metapopulation theory explains species persistence through dispersal-linked populations. This study links theory and conservation to predict reintroduction success in human-altered landscapes. Using the Crested Ibis (Nipponia nippon) as a model system, we combined spatially explicit habitat modeling with stochastic population viability analysis to assess how dispersal mediates persistence across wild and reintroduced populations in a metapopulation context. Our integrated approach identified 15,216 km² of potential habitat and a 95.64 km least-cost pathway linking wild population and reintroduced population. Projections over 50-year simulations revealed that dispersal significantly enhanced metapopulation viability, enabling population size to reach 17,846 individuals (92.37 % of carrying capacity). Conversely, population isolation would lead to a 15% decline in reintroduced population. Our simulations demonstrated that environmental stressors (including catastrophic events and predation pressure) reduced overall metapopulation size by 61.8% and 22.7% respectively when dispersal was absent. However, active dispersal effectively mitigated these impacts, maintaining long-term quasi-extinction probabilities at 0.17. The analysis revealed a clear source-sink dynamic, with the wild population serving as a stable source population, while the reintroduced population remained dependent on metapopulation connectivity for persistence.

PubMedCurrent zoology2026-05-28

Deer fear bear? A test of nonconsumptive effects on sika deer by an omnivorous Asiatic black bear.

Tsunoda Hiroshi H, Enari Hiroto H, Enari Haruka S HS

Nonconsumptive effects (NCEs) on prey animals by predators have received considerable interest in wildlife ecology and conservation. However, NCEs by large carnivore species with omnivorous diet still remain unclear. The Asiatic black bear (Ursus thibetanus) is widely found in eastern parts of the Eurasian Continent, including Honshu and Shikoku Islands of Japan. At present, this bear species is the only large carnivore in the region as a typical omnivore that occasionally predates sika deer (Cervus nippon). If sika deer recognize predation threats from black bears, then the NCEs by bears will provoke antipredator behavioral responses by the deer. In testing this hypothesis, we evaluated the spatial and temporal overlaps between bears and deer as well as compared the vigilance level and spatiotemporal avoidance observed in sika deer between bear-active and -inactive years, using camera trapping in an agroforest landscape in Fukushima, eastern Japan. Consequently, we found little changes in deer behaviors between bear-active and -inactive years, indicating that sika deer neither exhibited spatial partitioning and spatiotemporal avoidances from black bears nor increased their vigilance even in bear-active year. We concluded that our study showed no significant NCE of omnivorous Asiatic black bears on sika deer.

+2737 more articles available with a free account

Sign up free to view all articles →

Ask about prasterone